Pharmaceuticals

Increasing Prevalence Of Autoimmune Diseases Driving The Market Due To Rising Cases Triggering Heart Inflammation Is Supporting Development Across The Pericarditis Drugs Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Pericarditis Drugs Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The pericarditis drugs market has experienced substantial expansion in recent years. It will grow from $3.31 billion in 2025 to $3.61 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. This historical growth can be ascribed to several factors, including elevated diagnosis rates for inflammatory cardiac conditions, the presence of well-established NSAID therapies, an expanding cardiology care infrastructure, the increasing utilization of colchicine-based treatments, and refined clinical guidelines.

The pericarditis drugs market is projected to experience substantial growth in the upcoming years, with an anticipated expansion to $5.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. This projected growth can be attributed to factors such as the increasing development of biologic and immunomodulatory drugs, a rising focus on personalized cardiac care, the expansion of outpatient and homecare treatment models, growing investment in cardiovascular research, and increasing awareness of rare inflammatory heart diseases. Key trends during this forecast period are expected to include the increasing adoption of targeted anti-inflammatory therapies, a rising use of combination drug regimens, a growing focus on recurrent pericarditis management, the expansion of hospital-based treatment protocols, and enhanced monitoring of treatment outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30351&type=smp

What Are The Main Drivers Accelerating The Growth Of The Pericarditis Drugs Market?

The growing occurrence of autoimmune conditions is projected to boost the expansion of the pericarditis drugs market in the future. Autoimmune diseases involve the immune system erroneously targeting the body’s healthy cells and tissues. This increase in prevalence primarily stems from environmental shifts that interfere with the immune system, leading it to attack healthy tissues by mistake. Pericarditis medications are beneficial amidst the rising incidence of autoimmune diseases because numerous autoimmune disorders can induce pericarditis, which is an inflammation of the heart’s outer membrane. These medications assist in lowering inflammation, alleviating symptoms, and averting complications, thus treating pericarditis resulting from autoimmune processes. For example, in September 2023, data from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization focused on improving the lives of individuals with Crohn’s disease and ulcerative colitis, indicated that over 320,000 people in Canada suffered from inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 in 2023. Given an anticipated annual increase of 2.44%, it is projected that 1.1% of the population, equating to 470,000 Canadians, will have IBD by 2035. Consequently, the growing frequency of autoimmune diseases is stimulating the expansion of the pericarditis drugs market.

How Is Segment Classification Applied In The Pericarditis Drugs Market?

The pericarditis drugs market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine, Corticosteroids, Other Drug Class

2) By Route Of Administration: Oral, Intravenous, Intramuscular, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Therapeutic Application: Acute Pericarditis Treatment, Recurrent Pericarditis Management, Post-Cardiac Surgery, Pericardial Effusion Management

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Aspirin, Indomethacin, Naproxen, Diclofenac

2) By Colchicine: Oral Colchicine, Intravenous Colchicine

3) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

4) By Other Drug Class: Immunosuppressive Agents, Biologic Agents, Analgesics, Antibiotics

What Trends Are Driving Changes In The Pericarditis Drugs Market?

Major companies in the pericarditis drugs market are concentrating on developing innovative products, such as oral anti-inflammatory therapies, to enhance treatment accessibility and reduce recurrence rates for patients with recurrent pericarditis. An oral anti-inflammatory therapy is a small-molecule formulation designed to modulate inflammatory pathways and prevent disease relapse through systemic, non-injectable administration. For instance, in April 2025, Cardiol Therapeutics Inc., a Canada-based clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases, initiated a Phase III clinical trial for CardiolRx. This investigational therapy is engineered to target inflammasome pathway activation, a central mechanism in pericarditis-related inflammation and fibrosis. Its development marks progress toward offering a convenient, oral, non-immunosuppressive treatment option that could broaden therapeutic choices for recurrent pericarditis patients.

Which Industry Players Are Present In The Pericarditis Drugs Market?

Major companies operating in the pericarditis drugs market are Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals USA Inc., Zydus Lifesciences Limited, Kiniksa Pharmaceuticals, Camber Pharmaceuticals Inc., Scilex Holding Company, Solara Active Pharma Sciences, Alkaloids Bioactives Pvt. Ltd., Alchem International Pvt. Ltd., Sarv Biolabs Pvt. Ltd., Midas Pharma GmbH, AdvaCare Pharma, Actavis GmbH, Enomark LLC, Honour Lab Limited.

Access The Complete Pericarditis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/global-pericarditis-drugs-market-report

Which Area Represents The Largest Portion Of The Pericarditis Drugs Market?

North America was the largest region in the pericarditis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pericarditis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pericarditis Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30351&type=smp

Browse Through More Reports Similar to the Global Pericarditis Drugs Market 2026, By The Business Research Company

Pericarditis Market Report 2026

https://www.thebusinessresearchcompany.com/report/pericarditis-global-market-report

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795